PD-MitoQUANT is one of twelve research projects launched by the Innovative Medicines Initiative, Europe’s biggest public and private collaboration in life sciences, which aim to better understand and develop treatments for neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. PD-MitoQUANT has joined forces with these research projects on the Neuronet platform to aid progress and expedite the delivery of novel treatments. A memorandum of understanding was jointly signed by Coordinator Prof Jochen Prehn, RCSI and Carlos Díaz, Coordinator of Neuronet on October 9, 2019.
Neuronet aims to help scientists identify gaps in research, make findings more visible for society as a whole and create links between Innovative Medicines Initiative projects and other international research initiatives. Learn more about the Neuronet project here: https://www.imi-neuronet.org/
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821522. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.
The material presented and views expressed here reflect the author’s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.